ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
IBRX - ImmunityBio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.00
DETAILS
HIGH:
$12.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$12.00
UPSIDE:
23.84%
Stock News
State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX
State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,398,438 shares of the company's stock after buying an additional 3,690,335 shares during the period. State Street
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRX
Tidal Investments LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 252,048 shares of the company's stock, valued at approximately $2,207,000. Several other hedge funds and other institutional investors have also
ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
ImmunityBio: None Of The Moonshots Is Priced In
ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX
Canada Pension Plan Investment Board acquired a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,200 shares of the company's stock, valued at approximately $615,000. A number
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer and Check
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.
Bell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRX
Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 75,050 shares of the company's stock, valued at approximately $657,000. A number of other large investors have also
Bank of America Corp DE Increases Position in ImmunityBio, Inc. $IBRX
Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,447,843 shares of the company's stock after purchasing an additional 65,340 shares during the quarter. Bank of
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage biotechnology company, today announced financial and operational results for the second quarte
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first quarter of 2026. The Company also advanced multiple regulatory and clinical programs across its immunotherapy pipeline while achieving its eighth consecutive quarter of.
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.'s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination wit.
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)
ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.
Price Targets
ImmunityBio price target lowered to $12 from $13 at BTIG
$12.00
(was $7.76)
BTIG
Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler
$12.00
(was $9.20)
Edward Tenthoff
·
Piper Sandler
ImmunityBio price target raised to $15 from $10 at H.C. Wainwright
$15.00
(was $9.71)
H.C. Wainwright
ImmunityBio price target raised to $7 from $5 at Piper Sandler
$7.00
(was $5.52)
Piper Sandler
ImmunityBio initiated with a Buy at BTIG
$6.00
(was $2.42)
Justin Zelin
·
BTIG
Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline
$8.00
(was $4.12)
Kelly Shi
·
Jefferies